Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.
Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, Galus R, Etoh T, Mihara R, Yoshida H, Stewart J, Kabashima K; XCIMA Study Group. Ruzicka T, et al. N Engl J Med. 2017 Mar 2;376(9):826-835. doi: 10.1056/NEJMoa1606490. N Engl J Med. 2017. PMID: 28249150 Free article. Clinical Trial.
Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3.
Reich K, Simpson E, Wollenberg A, Bissonnette R, Abe M, Cardillo T, Janes J, Sun L, Chen S, Silverberg JI. Reich K, et al. Br J Dermatol. 2023 Feb 10;188(2):208-217. doi: 10.1093/bjd/ljac057. Br J Dermatol. 2023. PMID: 36763879 Clinical Trial.
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
Blauvelt A, Thyssen JP, Guttman-Yassky E, Bieber T, Serra-Baldrich E, Simpson E, Rosmarin D, Elmaraghy H, Meskimen E, Natalie CR, Liu Z, Xu C, Pierce E, Morgan-Cox M, Garcia Gil E, Silverberg JI. Blauvelt A, et al. Br J Dermatol. 2023 May 24;188(6):740-748. doi: 10.1093/bjd/ljad022. Br J Dermatol. 2023. PMID: 36994947 Clinical Trial.
Treat-to-target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitis.
Renert-Yuval Y, Del Duca E, Arents B, Bissonnette R, Drucker AM, Flohr C, Guttman-Yassky E, Hijnen D, Kabashima K, Leshem YA, Paller AS, Silverberg JI, Simpson EL, Spuls P, Vestergaard C, Wollenberg A, Irvine AD, Thyssen JP. Renert-Yuval Y, et al. Among authors: simpson el. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):42-51. doi: 10.1111/jdv.19506. Epub 2023 Sep 21. J Eur Acad Dermatol Venereol. 2024. PMID: 37700595 Review.
The vIGA-AD scale for atopic dermatitis: Uptake in the past 5 years and position of the International Eczema Council.
Bissonnette R, Simpson E, Eichenfield LF, Guttman-Yassky E, Silverberg JI, Beck LA, Mija L, Thyssen JP, Bieber T, Kabashima K, Siegfried E, Stingl G, van de Kerkhof P, Yosipovitch G, Paul C, Paller AS. Bissonnette R, et al. J Eur Acad Dermatol Venereol. 2024 Mar;38(3):e291-e295. doi: 10.1111/jdv.19627. Epub 2023 Nov 22. J Eur Acad Dermatol Venereol. 2024. PMID: 37943170 No abstract available.
Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001).
Silverberg JI, Strober B, Feinstein B, Xu J, Guttman-Yassky E, Simpson EL, Li P, Longphre M, Song J, Guo J, Yun J, Williams B, Pan W, Ho S, Collazo R, Wei Z. Silverberg JI, et al. Among authors: simpson el. J Allergy Clin Immunol. 2024 Apr;153(4):1040-1049.e12. doi: 10.1016/j.jaci.2023.11.924. Epub 2023 Dec 28. J Allergy Clin Immunol. 2024. PMID: 38157942 Clinical Trial.
Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study.
Guttman-Yassky E, Simpson EL, Reich K, Kabashima K, Igawa K, Suzuki T, Mano H, Matsui T, Esfandiari E, Furue M. Guttman-Yassky E, et al. Among authors: simpson el. Adv Ther. 2024 Mar;41(3):928-931. doi: 10.1007/s12325-023-02755-z. Epub 2024 Jan 8. Adv Ther. 2024. PMID: 38185777 Free PMC article. Clinical Trial.
Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies.
Simpson EL, Bissonnette R, Chiesa Fuxench ZC, Kallender H, Sturm D, Ren H, Stein Gold LF. Simpson EL, et al. J Dermatolog Treat. 2024 Dec;35(1):2310633. doi: 10.1080/09546634.2024.2310633. Epub 2024 Jan 31. J Dermatolog Treat. 2024. PMID: 38297490 Free article.
362 results